Creative Medical Technology Q2 2025 Earnings Report

Creative Medical Technology EPS Results

• Actual EPS: -$0.48
• Consensus EPS: -$0.63
• Beat/Miss: Beat by +$0.15
• One Year Ago EPS: N/A

Creative Medical Technology Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Creative Medical Technology Announcement Details

• Quarter: Q2 2025
• Date: 8/8/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Creative Medical Technology (NASDAQ:CELZ) is a biotechnology company focused on developing regenerative medicine and cell-based therapies. The company’s research programs are aimed at conditions involving inflammation, autoimmune dysfunction, tissue damage and sexual health.

Its pipeline has included ImmCelz, an immunomodulatory cell-therapy platform, as well as CaverStem for erectile dysfunction, FemCelz for female sexual health, KneeCelz for knee-related conditions and StemSpine for spinal disorders. These programs are investigational and are intended to support the company’s broader effort to use cellular therapies in place of, or alongside, conventional treatment approaches.

Creative Medical Technology Holdings is based in Phoenix, Arizona, and has focused primarily on developing therapies for the U.S. market. The company has operated as a publicly traded biotechnology business under the Nasdaq symbol CELZ, with its programs generally remaining in the research and clinical-development stages rather than being broadly marketed as approved pharmaceutical products.